Adoptive T cell therapy 2
AssigneesWestmead Institute For Medical Research, The University of Sydney, Western Sydney Local Health District, New South Wales Health Pathology
InventorsEmily Blyth, Leighton Clancy, David Gottlieb, Kenneth Micklethwaite
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions comprising isolated T cells, with activity against a fungal antigen, a viral antigen or a tumour antigen, wherein the composition comprises a defined number or defined ratio of T cells. Described herein are compositions comprising at least two populations of T cells, the compositions being suitable for treating various diseases and disorders.
Claims22
A composition comprising at least two populations of T cells, wherein each population has been separately contacted with at least one antigen from a different fungus, virus or tumor, wherein each population comprises T cells reactive with the at least one antigen from the different fungus, virus or tumor, wherein the composition comprises a defined number or defined ratio of T cells from each population, and wherein the defined number or defined ratio is based on a subject's clinical diagnosis, a subject's serology or infectious status, a subject's previous serology or infectious status, or a known antigen profile for a tumor or infection.
Dependencies are inferred from the claim text.